STTK (Shattuck Labs Inc) Market Value to Book Value Ratio

Official company branding of shattucklabs.com (STTK)

Shattuck Labs, Inc. (STTK) specializes in developing advanced oncology treatments. The stock price trend illustrates successes in diversifying therapies for solid tumors and leukemias via the ARC system, while the current metric stands at 2.77. Research costs and potential side effects raising concerns over capital dilution persist; however, the patenting of developments ensures global growth with minimal production costs.

STTK shattucklabs.com: Market Value to Book Value in the range 07/04/2022 - 10/28/2026
Original product of shattucklabs.com

The development of Shattuck Labs, Inc. (STTK) correlates directly with the success of clinical trials for oncology drugs. Analyzing the change in the market value to book capitalization ratio allows for an assessment of the market premium over assets. This metric divides the company's market value by its net equity, revealing the degree of stock overvaluation. The current value of 2.77 reflects the balance between investor expectations and actual R&D expenditures. This confirms the stability of the issuer's financial reserve.

Main competitors

ARGX: Market Value to Book Value Ratio|BNTX (biontech.de) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GOSS|Market Value to Book Value Ratio KalVista Pharmaceuticals KALV|Capitalization to Book Value Ratio septerna.com (SEPN)|PVLA: Market Capitalization to Book Value Ratio|Savara Inc - Market-to-Book Ratio|Market Value to Book Value Ratio RIGL (Rigel Pharmaceuticals Inc)|ANAB - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio Astria Therapeutics ATXS|engene.com (ENGN) - Market Value to Book Value|RAPT (RAPT Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Aerovate (JBIO)|Market Cap to Net Assets Ratio Aclaris|Market Cap to Book Value Multiple Kyverna Therapeutics, Inc KYTX|Market Cap to Net Assets Ratio Tiziana Life Sciences (TLSA)|CABA - Market Cap to Book Value Multiple|Ventyx Biosciences, Inc. - Market Cap to Net Assets Ratio|THTX - Market Capitalization to Book Value Ratio|AVTX (Avalo Therapeutics Inc.) - Market Capitalization to Book Value Ratio|ELDN (Eledon Pharmaceuticals, Inc) - Market Cap to Net Assets Ratio|AGEN (Agenus) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio climbbio.com (CLYM)|Zura Bio (ZURA) - Market Cap to Net Assets Ratio|Market Value to Book Value ATYR (aTyr Pharma Inc)|Market Value to Book Value Ratio Adagene Inc. ADAG|Market Value to Book Value Ratio ImageneBio IMA|Equillium Bio - Market Capitalization to Book Value Ratio|CNTB - Market Capitalization to Book Value Ratio|immunic-therapeutics.com (IMUX) - Market Capitalization to Book Value Ratio|ATRA (Atara Bio) - Market Value to Book Value Ratio|IFRX: Market Value to Book Value Ratio|Market Capitalization to Book Value X4 Pharmaceuticals, Inc (XFOR)|Adicet Bio (ACET) - Market Cap to Net Assets Ratio|Market Value to Book Value celularity.com (CELU)|Market Capitalization to Book Value Ratio INMB|Barinthus Biotherapeutics PLC - Market Capitalization to Book Value|Kezar Life Sciences, Inc (KZR) - Market Value to Book Value Ratio|SABS - Capitalization to Book Value Ratio|AKTX (Akari Therapeutics) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Enlivex Therapeutics Ltd.|QTTB: Market Cap to Net Assets Ratio|Market Capitalization to Book Value GOVX|EDSA (Edesa) - Market Value to Book Value Ratio|Market Capitalization to Book Value iBio Corporation IBIO|Market Cap to Net Assets Ratio Carisma Therapeutics Inc. (CARM)|XTLB - Market Cap to Book Value Multiple|Market Cap to Net Assets Ratio Bolt Bio BOLT|HCWB: Market Cap to Book Value Multiple|APVO: Market Value to Book Value Ratio|AIM (aimimmuno.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Aditxt Inc. ADTX|Market Capitalization to Net Assets gribio.com|XORTX Therapeutics (XRTX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Vyome Holdings Inc. (HIND)|Market Capitalization to Book Value Ratio REVB (Revelation Bio)|Indaptus Corp - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Scinai Immunotherapeutics (SCNI)|CALI: Market Value to Book Value|AFMD (affimed.com) - Market Value to Book Value Ratio|Allakos (ALLK) - Market Cap to Net Assets Ratio|HOOK (HOOKIPA Pharma, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio IGM Bio (IGMS)|iTeos Therapeutics (ITOS) - Market Cap to Net Assets Ratio|Market Value to Book Value oceanbiomedical.com (OCEA)|Market Capitalization to Book Value Ratio TCBP|Third Harmonic Bio Inc. - Market Capitalization to Book Value